#### Raw data belonging to:

Essawy, Aya; Mehrez, Mai; Zaki, Sara; El Garem Hassan; Sabri, Nagwa (2021), New incidence or recurrence her Subject initials were removed for the confidentiality of the data

The rest of the volunteers information were removed also for the confidentiality

All medical history, physical examination, laboratory values, inclusion and exclusion criteria are noted for eac All partipoipants signed an informed consent before being enrolled in the study, and attached the form of the Meta data for Basal data for SD group file

Column	entry value	unit	explanation (for Sofo: NA=Non ablicable
Α	Basal ALT numerica	l IU	ALT value at the start of the study
В	Basal AST numerica	l IU	AST value at the start of the study
С	Basal WBC numerica	I 103/L	WBCs value at the start of the study
D	Basal bilirt numerica	l mg/dl	Bilirubin value at the start of the study
Е	Basal albui numerica	l mg/dl	Albumin value at the start of the study
F	Basal INR numerica	l NA	INR value at the start of the study
G	Basal serui numerica	l mg/dl	Serum creatinine value at the start of the study
Н	Basal Hem numerica	l g/L	Hemoglubin value at the start of the study
1	Basal plate numerica	I 103/L	platelet value at the start of the study
J	Basal AFP numerica	I ng/ml	AFP value at the start of the study
K	Basal Child numerica	l NA	Child score value at the start of the study

#### Meta data for Basal data for SDR group file

Column	entry	value	unit	explanation (for Sofosbuvir/Daclatasvir/ Ribavirin group)
Α	Basal ALT	numerical	IU	ALT value at the start of the study
В	Basal AST	numerical	IU	AST value at the start of the study
С	Basal WB	C numerical	10 3 /L	WBCs value at the start of the study
D	Basal bilir	ι numerical	mg/dl	Bilirubin value at the start of the study
E	Basal albu	ıı numerical	mg/dl	Albumin value at the start of the study
F	Basal INR	numerical	NA	INR value at the start of the study
G	Basal seru	ıı numerical	mg/dl	Serum creatinine value at the start of the study
Н	Basal Hen	n numerical	g/L	Hemoglubin value at the start of the study
1	Basal plat	e numerical	10 3 /L	platelet value at the start of the study
J	Basal AFP	numerical	ng/ml	AFP value at the start of the study
K	Basal Chil	d numerical	NA	Child score value at the start of the study

#### Meta data for EOT data for SD group file

Column	entry	value	unit	explanation (for Sofosbuvir/Daclatasvir group)
Α	EOT ALT	numerical	IU	ALT value at the end of treatment ( at week 12)
В	EOT AST	numerical	IU	AST value at the end of treatment ( at week 12)
С	EOT WBC	s numerical	10 3 /L	WBCs value at end of treatment ( at week 12)
D	EOT biliru	k numerical	mg/dl	Bilirubin value at the end of treatment ( at week 12)
E	EOT albun	r numerical	mg/dl	Albumin value at the end of treatment ( at week 12)
F	EOT INR	numerical	NA	INR value at the end of treatment ( at week 12)
G	EOT serun	r numerical	mg/dl	Serum creatinine value at theend of treatment ( at week 12)
Н	EOT Hemo	o numerical	g/L	Hemoglubin value at the end of treatment ( at week 12)
1	EOTplatel	e numerical	10 3 /L	platelet value at the end of treatment ( at week 12)
J	EOT AFP	numerical	ng/ml	AFP value at the end of treatment ( at week 12)

## Meta data for EOT data for SDR group file

Column	entry	value	unit	explanation (for Sofosbuvir/Daclatasvir/Ribavirin group)
Α	EOT ALT	numerical	IU	ALT value at the end of treatment ( at week 12)
В	EOT AST	numerical	IU	AST value at the end of treatment ( at week 12)
С	EOT WBCs	numerical	10 3 /L	WBCs value at end of treatment ( at week 12)
D	EOT bilirul	numerical	mg/dl	Bilirubin value at the end of treatment ( at week 12)
E	EOT album	numerical	mg/dl	Albumin value at the end of treatment ( at week 12)
F	EOT INR	numerical	NA	INR value at the end of treatment ( at week 12)
G	EOT serun	numerical	mg/dl	Serum creatinine value at theend of treatment ( at week 12)
Н	EOT Hemo	numerical	g/L	Hemoglubin value at the end of treatment ( at week 12)
1	EOTplatele	numerical	10 3 /L	platelet value at the end of treatment ( at week 12)
J	EOT AFP	numerical	ng/ml	AFP value at the end of treatment ( at week 12)
K	EOT Child	numerical	NA	Child score value at the end of treatment ( at week 12)

## Meta data for SVR 12 data for SD group file

Column	entry	value	unit	explanation (for Sofosbuvir/Daclatasvir group)
Α	SVR 12 Al	1 numerical	IU	ALT value at week 24
В	SVR 12AS	T numerical	IU	AST value at week 24
С	SVR 12W	B numerical	10 3 /L	WBCs value at week 24
D	SVR 12 bi	li numerical	mg/dl	Bilirubin value at week 24
Е	SVR 12 al	b numerical	mg/dl	Albumin value at week 24
F	SVR 12 IN	F numerical	NA	INR valueat week 24
G	SVR 12 se	r numerical	mg/dl	Serum creatinine value at week 24
Н	SVR 12 H	e numerical	g/L	Hemoglubin value at week 24
1	SVR 12 pl	a numerical	10 3 /L	platelet value at week 24
J	SVR 12 AF	-I numerical	ng/ml	AFP value at week 24
K	SVR 12 Ch	ni numerical	NA	Child score value at week 24

## Meta data for SVR 12 data for SDR group file

Column	entry	value	unit	explanation (for Sofosbuvir/Daclatasvir/Ribavirin group)
Α	SVR 12 AL	. numerical	IU	ALT value at week 24
В	SVR 12 AS	numerical	IU	AST value at week 24
С	SVR 12 W	E numerical	10 3 /L	WBCs value at week 24
D	SVR 12 bil	li numerical	mg/dl	Bilirubin value at week 24
E	SVR 12 alk	o numerical	mg/dl	Albumin value at week 24
F	SVR 12 IN	F numerical	NA	INR valueat week 24
G	SVR 12 SC	îr numerical	mg/dl	Serum creatinine value at week 24
Н	SVR 12 He	numerical	g/L	Hemoglubin value at week 24
1	SVR 12 pla	a numerical	10 3 /L	platelet value at week 24
J	SVR 12 AF	I numerical	ng/ml	AFP value at week 24
K	SVR 12 Ch	i numerical	NA	Child score value at week 24

## Meta data for basal data for HCC group file

Column	entry	value	unit	explanation (for patients who developed HCC in Sofosbuvir/Dacla
Α	Basal ALT	numerica	l IU	ALT value at the start of the study

В	Basal AST numerical IU	AST value at the start of the study
С	Basal bilirt numerical mg/dl	Bilirubin value at the start of the study
D	Basal albui numerical mg/dl	Albumin value at the start of the study
E	Basal WBC numerical 10 3 /L	WBCs value at the start of the study
F	Basal Hem numerical g/L	Hemoglubin value at the start of the study
G	Basal plate numerical 10 3 /L	platelet value at the start of the study
Н	Basal INR numerical NA	INR value at the start of the study
1	Basal AFP numerical ng/ml	AFP value at the start of the study
J	Basal serui numerical mg/dl	Serum creatinine value at the start of the study
K	Basal Child numerical NA	Child score value at the start of the study
L	Basal Glycanumerical %	Glycated Hemoglubin at the start of the study

## Meta data for EOT data for HCC group file

Column	entry	value	unit	explanation (for patients who developed HCC in Sofosbuvir/Dacla
Α	EOT ALT	numerical	IU	ALT value at the end of treatment ( at week 12)
В	<b>EOT AST</b>	numerical	IU	AST value at the end of treatment ( at week 12)
С	EOT biliru	ı numerical	mg/dl	Bilirubin value at the end of treatment ( at week 12)
D	EOT albur	r numerical	mg/dl	Albumin value at the end of treatment ( at week 12)
E	EOT WBC	:: numerical	10 3 /L	WBCs value at the end of treatment ( at week 12)
F	EOT Hemo	o numerical	g/L	Hemoglubin value at the end of treatment ( at week 12)
G	EOT plate	l numerical	10 3 /L	platelet valueat the end of treatment ( at week 12)
Н	EOT INR	numerical	NA	INR value at the end of treatment ( at week 12)
1	EOT AFP	numerical	ng/ml	AFP valueat the end of treatment ( at week 12)
J	EOT seru	n numerical	mg/dl	Serum creatinine valueat the end of treatment ( at week 12)
K	EOT Child	l numerical	NA	Child score value at the end of treatment ( at week 12)
L	EOT Glyca	ıt numerical	%	Glycated Hemoglubin at the end of treatment ( at week 12)

# Meta data for SVR12 data for HCC group file

Column	entry	value	unit	explanation (for patients who developed HCC in Sofosbuvir/Dacla
Α	SVR12 AL	T numerical	l IU	ALT value at week 24
В	SVR12AS	Γ numerical	l IU	AST value at week 24
С	SVR12 bi	li numerical	l mg/dl	Bilirubin valueat week 24
D	SVR12 alb	o numerical	l mg/dl	Albumin value at week 24
E	SVR12 W	B numerical	103/L	WBCs value at week 24
F	SVR12 He	r numerical	l g/L	Hemoglubin value at week 24
G	SVR12 pla	at numerical	103/L	platelet value at week 24
Н	SVR12 INI	R numerical	l NA	INR value at week 24
1	SVR12 AF	P numerical	l ng/ml	AFP value at week 24
J	SVR12 se	r numerical	l mg/dl	Serum creatinine value at week 24
K	SVR12 Ch	ni numerical	l NA	Child score valueat week 24

Meta data	data for Demographic data for SD group file				
column	entry	value	remarks		
Α	patient co	NA	study coding of the patients in SD group		
В	Sex	categorica	in the software analysis 1= male,2= female		
С	Age	numerical			

Meta data for Demographic data for SDR group file

column entry value remarks

A patient co(NA study coding of the patients in SDR group
B Sex categorica in the software analysis 1= male,2= female

C Age numerical

Meta data for diabetic patients in SD group with their basal glycated values file

column entry value remarks

A patient co(NA study coding of the patients in SD group

B DM categorica only diabetic patients in the group are included in this table

C basal glyca numerical

Meta data for diabetic patients in SDR group with their basal glycated values file

column entry value remarks

A patient co(NA study coding of the patients in SDR group

B DM categorica only diabetic patients in the group are included in this table

C basal glyca numerical

Meta data for EOT glycated hemoglobin for both groups file

column entry value
A glycated h numerical
B glycated h numerical

vatocellular carcinoma (HCC) in genotype 4 hepatitis C virus	treated with sofosbuvir/daclatasvir with or withou

ıt ribavirin